ELISA ADARB1 anti-

Quantity :100µL Clone Number: Aliases:tibody; ADARB1 antibody; 1700057H01Rik antibody; ADAR2 antibody; ADAR2a antibody; ADAR2a L1 antibody; ADAR2a L2 antibody; ADAR2a L3 antibody; ADAR2b antibody; ADAR2c antibody; ADAR2d antibody; ADAR2g antibody; Adarb1 antibody; Adenosine deaminase; RNA specific; 2 antibody; Adenosine deaminase; RNA specific; B1 (homolog of rat RED1) antibody; Adenosine deaminase; RNA specific; B1 (RED1 homolog rat) antibody; Adenosine deaminase; RNA specific; B1 antibody; AW124433 antibody; AW558573 antibody; BB220382 antibody; D10Bwg0447e antibody; Double stranded RNA specific editase 1 antibody; Double-stranded RNA-specific editase 1 antibody; DRABA2 antibody; DRADA2 antibody; dsRNA adenosine deaminase antibody; EC 3.5.-.- antibody; dsRNA adenosine deaminase DRADA2 antibody; dsRNA adenosine deaminase DRADA2b; EC 3.5 antibody; OTTHUMP00000115341 antibody; OTTHUMP00000115342 antibody; RED 1 antibody; RED1_ antibody; RNA editase antibody; RNA editase 1 antibody; RNA editing deaminase 1 antibody; RNA editing enzyme 1 antibody; RNA editing enzyme 1; rat; homolog of antibody; RNA specific adenosine deaminase B1 antibody; RNA-editing deaminase 1 antibody; RNA-editing enzyme 1 antibody Product Type:Polyclonal Antibody Immunogen Species:Homo sapiens () UniProt ID:P78563 Immunogen:SyntheQuantityd peptide derived from internal of ADARB1. Raised in:Rabbit Reactivity:, Mouse, Rat Tested Applications:ELISA, WB; WB:1:500-1:3000 Background:Catalyzes the hydrolytic deamination of adenosine to inosine in double-stranded RNA (dsRNA) referred to as A-to-I RNA editing. This may affect gene expression and function in a number of ways that include mRNA translation by changing codons and hence the amino acid sequence of proteins; pre-mRNA splicing by altering splice site recognition sequences; RNA stability by changing sequences involved in nuclease recognition; genetic stability in the case of RNA virus genomes by changing sequences during viral RNA replication; and RNA structure-dependent activities such as microRNA production or targeting or protein-RNA interactions. Can edit both viral and cellµLar RNAs and can edit RNAs at mµLtiple sites (hyper-editing) or at specific sites (site-specific editing). Its cellµLar RNA substrates include: bladder cancer-associated protein (BLCAP), neurotransmitter receptors for glutamate (GRIA2 and GRIK2) and serotonin (HTR2C), GABA receptor (GABRA3) and potassium voltage-gated channel (KCNA1). Site-specific RNA editing of transcripts encoding these proteins resµLts in amino acid substitutions which consequently alter their functional activities. Edits GRIA2 at both the Q/R and R/G sites efficiently but converts the adenosine in hotspot1 much less efficiently. Can exert a proviral effect towards immunodeficiency virus type 1 (HIV-1) and enhances its replication via both an editing-dependent and editing-independent mechanism. The former involves editing of adenosines in the 5'UTR while the latter occurs via suppression of EIF2AK2/PKR activation and function. Can inhibit cell proliferation and migration and can stimµLate exocytosis. Mittaz L., Genomics 41:210-217(1997). Lai F., Mol. Cell. Biol. 17:2413-2424(1997). Villard L., Somat. Cell Mol. Genet. 23:135-145(1997). Clonality:Polyclonal Isotype:IgG Purification Method:The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen. Conjµgate:Non-conjµgated Buffer:Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Form:liquid Stroage:Upon receipt, store at -20°C or -80°C. Avoid repeated freeze. Target Names:ADARB1 Research Areas:Epigenetics and Nuclear Signaling